{"efta_number": "EFTA00314225", "page_count": 15, "url": "https://epstein-data.com/EFTA00314225", "pdf_url": "https://epstein-data.com/pdf/EFTA00314225.pdf", "pages": [{"efta_number": "EFTA00314225", "page_number": 0, "text_content": "Quest \nDrogrostics\" \nReport Status: Final \nEPSTF.IN, JEFFREY \nPatient Information \nSpecimen Information \nClient Information \nF:PSTEIN, JEFFREY\nDOB: \nAGE: 65 \nGender: \nM \nPhone: \nPatient ID: \nI lealth ID: \nSpecimen: \nMR047987t. \nRequisition: 0006029 \nCollected: \n08/14/2018 \nReceived: \n08/1412018 /21:21 EDT \nReported: \n08/192018 / 13:55 EDT \nClient N: \n56W5265 \nMOSKOWITZ, BRUCL W \nIIRUCE MOSKOWITZ, MD \nAttn: NATIONWIDE ACCOUNT \n1411 N FLAGLER DR STE 7100 \nWEST PALM BEACIL FL 33401.3418 \nTest Name \nPTH, INTACT AND CALCIUM \nPTH, INTACT \nPARATHYROID HORMONE, \nINTACT \nInterpretive Guide \nIntact \nIn Range \nOut Of Range \nReference Range \n94 H \nCalcium \nNormal Parathyroid \nNormal \nNormal \nIlypoparathyroidism \nLow or Low Normal \nLow \nHyperparathyroidlam \nPrimary \nNormal or High \nHigh \nSecondary \nHigh \nNormal or Low \nTertiary \nHigh \nHigh \nNon-Parathyroid \nHypercalcemia \nLow or Low Normal \nHigh \nCALCIUM \n9.8 \n14-64 pg/mL \nLab \n4/1 \n8.6-10.3 mg/dL \nMI \nPERFORMING SITE: \nMI \ncast Dl Mlq KrMi Nlasll. 'tom nnttirRCE \n‘np.o.oduLikei the taints^ Ileac. 01 I N I IMAM:MD Pill) (11A Ilallon1134 \nCLIENT SERVICES: 866.697.8378 \nSPECIMEN: MR0479871. \nQtiol. Quasi Dlatelostk; Iht owxhatil lag. sad sit ea...dried Quell Dbatausilrb mirk. art the trademark% orciaral \nPAGE I OF I \nEFTA00314225\n", "char_count": 1286}, {"efta_number": "EFTA00314225", "page_number": 1, "text_content": "411)()uest \n°tannest ts \n—• \nReport Status: Partial \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen Information \nClient Information \nEPSTEIN, JEFFREY \n110B: \nAGE: 65 \nt ;ender: \nM \nMIMI:: \nPatient ID: \nI lealth ID: \nSpecimen: \nMR0479851. \nRequisition: 0006030 \nCollected: \n08/14/2018 \nReceived: \n08115/2018 / 15:11 EDT \nReported: \n08/16/2018 107.59 EDT \nClient a: 78300020 \n56W5265 \nMOSKOWITZ, BRUCE W \nBRUCE MOSKOWITZ, MD \nAtm: NATIONWIDE ACCOUNT \n1411 N PLAGLER DR STE 7100 \nWEST PALM BEACH. EL 33401-3418 \nTest Name \nLIPID PANEL, STANDARD \nCHOLESTEROL, TOTAL \nHDL CHOLESTEROL \nTRIOLTCERIDES \nLDL-CHOLESTEROL \nIn Range \nOut Of Range \n233 H \n29 L \n541 H \nLDL cholesterol not calculated. TrigLyceride levels \ngreater than 400 mg/dL invalidate calculated LW, results. \nReference range: <100 \nDesirable range <100 mg/dL for primary prevention; \n<70 mg/dL for patients with CHD or diabetic patients \nwith > or • 2 CHD risk factors. \nLDL-C is now calculated using the Martin-Hopkins \ncalculation, which is a validated novel method providing \nbetter accuracy than the Friedewald equation in the \nestimation of LDL-C. \nMar ' \n• \n• 2 1-20 a \nCHOL DL RATIO \nNON HDL CHOLESTEROL \n204 H \nFor patients with diabetes plus I major ASCVD risk \nfactor, treating to a non-HDL-C goal of <100 mg/dL \n(LDL-C of <70 mg/c1L) is considered a therapeutic \noption. \nHS CRP \n1.3 \nAverage relative cardiovascular risk according to \nMIA/CDC guidelines. \nFor ages >17 \nhs-CRP mg/L \n<1.0 \n1.0-3.0 \n3.1-10.0 \n>10.0 \nYears: \nRisk According to ARit/CDC Guidelines \nLower relative cardiovascular risk. \nAverage relative cardiovascular risk. \nHigher relative cardiovascular rink. \nConsider retesting in 1 to 2 weeks to \nexclude a benign transient elevation \nin the baseline CRP value secondary \nto infection or inflammation. \nPersistent elevation, upon retesting. \nmay be associated with infection and \ninflammation. \nHOMOCYSTEINE \n20.5 \nHomocysteine is increased by functional deficiency of \nfolate or vitamin 612. Testing for methy\n... [truncated, 2569 chars — for the full page use /api/corpus/document/EFTA00314225/1 or ?id=EFTA00314225&page=1]", "char_count": 2569}, {"efta_number": "EFTA00314225", "page_number": 2, "text_content": "40) Quest \nDiagnostics-\nReport Status: Partial \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen In fonnation \nClient Information \nEPSTEIN, JEFFREY \nDOB: \nAGE: 65 \nGender: \nM \nPatient II): \nHealth ID: \nSpecimen: \nMR047985L \nCollected: \nOW Is1/20I S \nReceived: \n0S/15/20I8 / 15:11 EDT \nReported: \n08/16,2018 / 07:59 EDT \nClient ii: \nMOSKOWITZ. BRUCE W \nTest Name \nCOMPREHENSIVE METABOLIC \nPANEL \nGLUCOSE \nIn Range \n95 \nOut Of Range \nReference Range \n65-99 mg/dL \nPasting reference interval \nLab \nMI \nUREA NITROGEN (DUNI \n22 \nCREATININE \n1.16 \nFor patients >49 yearn of age, the reference limit \nfor Creatinine is approximately 13t higher for people \nidentified as African-American. \neGPR NON-APR. AMERICAN \n66 \neGPR AFRICAN AMERICAN \n76 \nBUN/CREATININE RATIO \nNOT APPLICABLE \n7-25 mg/dL \n0.70-1.25 mg/dL \nOR • 60 mL/min/1.73m2 \n> OR ra 60 mL/m1n/1.73m2 \n6-22 (talc) \nSODIUM \n139 \n135-146 mmol/L \nPOTASSIUM \n4.4 \n3.5-5.3 mmol/L \nCHLORIDE \n105 \n98-110 mmol/L \nCARBON DIOXIDE \n23 \n20-32 mmol/L \nCALCIUM \n9.0 \n8.6-10.1 mg/c1L \nPROTEIN, TOTAL \n7.0 \n6.1-8.1 g/cIL \nALBUMIN \n4.2 \n3.6-5.1 g/dL \nGLOBULIN \n2.8 \n1.9-1.7 g/dt (talc) \nALBUMIN/GLOBULIN RATIO \n1.5 \n1.0-2.5 (talc) \nBILIRUBIN, TOTAL \n0.8 \n0.2-1.2 mg/di. \nALKALINE PHOSPHATASE \n55 \n40-115 U/L \nAST \n23 \n10-35 U/L \nALT \n35 \n9-46 U/L \nHEMOGLOBIN Ale \n5.7 H \n<5.7 i of total Hgb \nMI \nFor someone without known diabetes, a hemoglobin \nAle value between 5.7% and 6.44 is consistent with \nprediabetes and uhould be confirmed with a \nfollow-up test. \nFor someone with known diabetes, a value cit \nindicates that their diabetes is well controlled. A1c \ntargets should be individualized based on duration of \ndiabetes, age, comorbid conditions, and other \nconsiderations. \nThis assay result is consistent with an increased risk \nof diabetes. \nCurrently, no consensus exists regarding use of \nhemoglobin Aic (or diagnosis of diabetes for children. \nURIC ACID \n8.3 H \n4.0-8.0 mg/dL \nMI \nTherapeutic target (or gout patients: <6.n mg/dL \nTS\" \n2.31 \n0.40-4.50 \n14I\n... [truncated, 2345 chars — for the full page use /api/corpus/document/EFTA00314225/2 or ?id=EFTA00314225&page=2]", "char_count": 2345}, {"efta_number": "EFTA00314225", "page_number": 3, "text_content": "4iiiQuest \nelagmntKi.\nReport Status: Partial \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen Information \nClient Information \nEPSTEIN, JEFFREY \nDOB: \nAGE:65 \nGender \nM \nPatient ID: \nI learnt ID: \nSpecimen: \nMR047985L \nCollected: \n08114/2018 \nReceived: \n08/15/2018 / 15:11 EDT \nReported: \ndB/le/2018 / 07:59 EDT \nClient N: \nMOSKOWITZ. BRUCE W \nTest Name \nIn Range \nOut Of Range \nReference Range \nLab \nWESTERGREN \n9 \nc OR \n20 mm/h \nCBC (INCLUDES DIFP/PLT) \nMI \nWHITE BLOOD CELL COUNT \n5.9 \n3.8-10.8 Thousand/uL \nRED BLOOD CELL COUNT \n5.12 \n4.20-5.80 Million/uL \nHEMOGLOBIN \n15.1 \n13.2-17.1 g/dL \nHEMATOCRIT \n44.5 \n38.5-50.0 \nMCV \n86.9 \n80.0-100.0 fL \nMCII \n29.5 \n27.0-33.0 pg \nMCHC \n33.9 \n32.0-36.0 g/dL \nRDW \n13.8 \n11.0-15.0 \nPLATELET COUNT \n248 \n140-400 Thousand/uL \nMPV \n9.7 \n7.5-12.5 EL \nABSOLUTE NEUTROPHILS \n2879 \n1500-7800 cells/uL \nABSOLUTE LYMPHOCYTES \n2018 \n850-3900 cells/uL \nABSOLUTE MONOCYTES \n502 \n200-950 cells/uL \nABSOLUTE EOSINOPHILS \n443 \n15-500 colls/uL \nABSOLUTE BASOPHILS \n59 \n0-200 cells/uL \nNEUTROPHILS \n48.8 \nLYMPHOCYTES \n34.2 \nMONOCYTES \n8.5 \nEOSINOPHILS \n7.5 \nBASOPHILS \n1.0 \nURINALYSIS, COMPLETE \nMI \nSee Sndnote \nVITAMIN 612 \n371 \n200-1100 pg/m1 \nM1 \nPlease Note: Although the reference range for vitamin \nB12 is 200-1100 pg/mL, it has been reported that between \n5 and 10% of patients with values between 200 and 400 \npg/mt may experience neuropsychiatric and hematologic \nabnormalities due to occult B12 deficiency; less than IS \nof patients with values above 400 pg/mL will have symptoms. \nC-REACTIVE PROTEIN \n1.6 \nEXTRA BLUE-TOP TUBE \nAN EXTRA SPECIMEN WAS RECEIVED WITH NO TEST REQUESTED. \nTHE SPECIMEN WILL BE MAINTAINED IN STORAGE IN CASE \nADDITIONAL TESTING IS NEEDED. PLEASE CALL THE CLIENT \nSERVICE DEPARTMENT FOR FURTHER ASSISTANCE. \nPROLACTIN \n3.9 \nTESTOSTERONE, TOTAL \nMALES (ADULT), IA \nTESTOSTERONE, TOTAL, \nMALES (ADULT), IA \n150 L \nIn hypogonadal males, Testosterone, Total, LC/MS/MS, \nis the recommended assay due to the diminished \naccuracy of immunoassa\n... [truncated, 2412 chars — for the full page use /api/corpus/document/EFTA00314225/3 or ?id=EFTA00314225&page=3]", "char_count": 2412}, {"efta_number": "EFTA00314225", "page_number": 4, "text_content": "rajQuest \ntkagnost;c5-\nwe. \nReport Status: Partial \nEPSTEIN, JEFFREY \nPatient Information \nSpecimen Information \nSpecimen: \nKIR047985I. \nCollected: \n08/14/2018 \nReceived: \nOWI512018 !15:11 EDT \nReported: \n08/1612018 I 07:59 EDT \nClient Information \nEPSTF:IN, JEFFREY \nDOB: \nAGE: 65 \nGender: \nAt \nPatient ID: \nHealth II): \nClient a: \nMaSKOWITZ, BRUCE W \nEndocrinology \nTest Name \nTT \nI rc• \nVitamin 0 Status \n25.0H Vitamin n: \nDeficiency: \ninsufficiency: \nOptimal: \n20 • \nor m \nc20 \n29 \n30 \nng/mL \nng/mL \nng/mL \nFor 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitatlon of D2 and D3 fractions is required. the \nOuestAssureD(TM) 25-OH VIT D. (O2.O3). LC/MS/MS is recommended. order code 92868 (patients >2yrs). \nFor more Information on this test, go to' \n(This link is being provided for informationaU \neducational purposes only.) \nResult \nReference Range \nLab \n30-100 ng/mL \nPhysician Comments \nPENDING TESTS: \nMERCURY. BLOOD \nPERFORMING SITE: \nMI \nttek‘T 111A0X0511COMAMI.102(0(0,1M11113 PARKWAV,M. \nit ttm$ utlt Ia.. mu, iltmai,  6111X I IIIAILCMDPIR4CtiA itallIMMI \nIP \n014 'MI IIIMM0SlICS•1411119. 1!:3 1. 104 LI R 4VE ,1AMPA. 1l I bil.:€1:4 ta.4 \nam.u. Ultlt ItORMS \n(1.14 Ifivit•OLYI \nCLIENT SERVICES: 866.697.8378 \nSPECIMEN: AIR0479851., \npunt. Qnnl Diagnostic% the aswdauA logo and all Snoclaird pore) MI/ignotlIts marls art the Iracleutarts of Qt.& btahauslits. \nPAGE 4 OF 4 \nEFTA00314229\n", "char_count": 1436}, {"efta_number": "EFTA00314225", "page_number": 5, "text_content": "Phone \nCarnegie Hill Radiology \n170 East 77th St \nNew York, NY 10073-1912 \nSteven D. Wolff, M.D., \nDirector \nPax \nCARDIAC AND CHEST CTA \nPATIENT: Epstein, Jeffrey \nDATE: July 29, 2018 \nAGE: 65 \nSIX: M \nICA \nREFERRING: Dr. Bernard Kruger \nHISTORY \nAbdominal pain. \nCOMPARISON \nTo 2)8/2006. \nTECHNIQUE \nA low-dose gated cardiac and chest CTA were performed before and after the intravenous \nadministration of 94 oft- of Isovue-370. The images were reviewed and reconstructed on a 3-D \nworkstation. \nFINDINGS \nThe coronary arteries originate normally from the aortic root and have a normal epicardial \ncourse. The left main is widely patent and free of plaque. In the proximal LAD there are focal \ncalcified and soft plaque causing 30% to 49% stenosis. In the mid LAD there are focal \ncalcifications causing 30% to 49% stenasis. The distal LAD is diffusely small in size with a small \nbulky calcification. The diagonal arteries are small in caliber. The circumflex Is widely patent. \nThe obtuse marginal arteries are small in caliber. The RCA is dominant. The proximal and mid \nRCA is widely patent. The distal RCA and PDA are small in caliber. \nThere is posterior right pleural thickening. No pleural or pericardial effusion is noted. There is \nno evidence for significant lymphadenopathy. There is diffuse thickening of the esophagus with \nfluid noted in the posterior medlastinum adjacent to the esophagus, which may be related to an \ninflammatory process. This was not seen previously. There is heterogeneity of the liver \nparenchyma, likely fatty liver. The ascending aorta measures 4.0 cm at the level of the sinuses of \nValsalva. In the lateral left ea rib there is a bone island noted. In the right lateral 8th rib there is a \nbone island noted. There are degenerative changes of the osseous structures. \nIMPRESSION \n1. The coronary calcium score is 84, placing the patient in the 25th to 50th percentile. It \npreviously measured 41. \n2. Nonobstructive atherosclerosis is noted in the LAD as des\n... [truncated, 2360 chars — for the full page use /api/corpus/document/EFTA00314225/5 or ?id=EFTA00314225&page=5]", "char_count": 2360}, {"efta_number": "EFTA00314225", "page_number": 6, "text_content": "Carnegie Hill Radiology \nCardiac and Chest aA \nEpstein, efircy \nJuly 29,2018 \nPage 2 of 2 \ninfectious process. Advise correlation with endoscopy. A short-term blowup chest CT with \ncontrast is recommended in 2 months to confirm resolution of these findings. \n4. Hepatic steatosis. \n5. There is thickening of the right posterior pleura, which may be due to infection and/or \ninflammation. \nM. Robed Peters, MD \nOfith44CotepAre Sonia, (212)01.11a \nEFTA00314231\n", "char_count": 459}, {"efta_number": "EFTA00314225", "page_number": 7, "text_content": "BIS Fax Server \n1/30/2018 9:03:40 AM PAGE \n2/004 \nFax Server \nRichardJ.10MA M.D. \nSteven A. Albert, MD. \nStephen D. Greenberg, MD \nDouglas R. [Thema; MD. \nGavin L Duke, MD. \nPaul S. Ohol, MD. \nSean K. Herman, M.D. \nRobed L. Ludwig, M.D. \n11mothyVV. Deyer, MD. \nJames W. Brady, M.D. \nGwen N. Harris, MD. \nMam J. Winer, MD, \nMark H. Plnab, \nGeorge Stases, MD. (rat) \nMorton Schneider, MD. (net) \nAlison Bender Halmos, M.D. (rot) \n519 & 523 East 72nd Sheol • NewYork, NY 10021 • 9 East 76Ih Street Al FM \"venue •New York, NY 10021 \n430 East 59th Street, Sutton Place • New York, NY10022 • 424 East Stith Mieet • New Yor K NY10128 \nTel:212-286-1575 • Fax 212.288-7016 •www.eastrterknaging.00m \nBRUCE W MOSKOWITZ, M.D. \n1411 NORTH RADLER DRIVE \nSUITE 7100 \nWEST PALM BEACH, FL 33401 \nPatient EPSTEIN, JEFFREY \nExam Date: 1/30/18 \nAce No: \nMRN: 0315192 \nDear Dr. Moskowitz, \nCT NECK \nClinical History: \n65 y/o male with elevated PTH, concem for parathyroid adenoma. \nTechnique: \nMultideteotor helical CT scans of the neckwere performed utilizing 40 parathyroid technique, from the \nsuperior orbital rim to the thoracic inlet using 2.5 mm slices, prior to and during the constant infusion of \nnonionic intravenous contrast. Multiphase postcontrast dynamic imaging was employed. Images were \nreconstructed at 1.25mm slice thicknesses at 1.25mm slice Intervals with corona! and sagittal \nreformats. \nComparison: \nNeck MRI performed 11/30/2016 \nFindings:,\nThe visualized brain parenchyma Is normal. \nThe orbital contents are partially excluded from the field of view but are grossly normal in appearance. \nEPSTEIN, JEFFREY ACS \nExam Date: vsorie not \nACCESS YOUR PATIENTS IMAGES AND REPORTS \nWINW.EASTRIVERNAGINO.CONI \nPET/CT • HIGH FIELD MRI • OPEN MR I- MULTIDETECTOR VOLUME CT (VCTJ • DONE DENSITY • NUCLEAR MEDICINE \nULTRASOUND • DIGITAL X•RAY • CORONA RY CT ANGIOGRAPHY • VIRTUAL COLONOSCOPY • CT/MR ANSIOORAPHY \nEFTA00314232\n", "char_count": 1921}, {"efta_number": "EFTA00314225", "page_number": 8, "text_content": "RIS Fax Server \n1/30/2018 9:03:40 AM PAGE \n3/004 \nfax Server \nThe masticator spaces are normal. \nThe mastoid air cells and tympanic) cavities aro clear. \nMid scattered paranasal sinus mucosal thickening is seen with areas appearing polypold In nature. \nFindings are worse along the left frontal drainage pathway which is occluded. \nA few of the maxillary and mandibular teeth have been endodonticalty treated. There is a left 2nd \nmandibular molar dental implant. Small bilateral mandibular tori are present \nThe nasopharyry is normal. Prominence of the bilateral palatine tonsils are seen without deep \nextension, likely reactive in nature. Punctate calcifications Involve both palatine tonsils, &city reflecting \nremote inflammation. Minimal prominence of the bilateral lingual tonsils is seen without deep extension, \nlikely reactive in nature. There is a tiny air-filled right Internal laryngocele, The hypopharynx and larynx \nare otherwise normal. The true cords are adducted. \nThe major salivary glands including the parotid, submandibular and sublingual glands are normal. \nThe thyroid is mildly heterogeneous. There is a 0.5 cm enhancing nodule within the posterior right \nmidpole of the thyroid. \nThere are no early enhancing parathyroid nodules. No discrete parathyroid mass is present. There Is \nno evidence for a parathyroid adenoma. \nThere is no suspicious or pathologically enlarged cervical chain lymphadenopathy. \nThere Is a partially imaged lipoma within the left supraclavicular fossa measuring 4.7 cm in greatest \ncranlocaudad dimension and 2.5 cm in greatest AP dimension. This is unchanged. \nThere Is a bovine configuration of the great vessels arising from the aortic arch, a normal anatomic \nvariant. There is patency of the major vessels of the neck. \nThe pericervical musculature, scalene musculature and stemocleidomastoid muscles are normal \nasymmetric atrophy. \nThe lung apices are clear. There is no suspicious mediastinal mass or evidence of ectopic parathyroid \nadenoma\n... [truncated, 2588 chars — for the full page use /api/corpus/document/EFTA00314225/8 or ?id=EFTA00314225&page=8]", "char_count": 2588}, {"efta_number": "EFTA00314225", "page_number": 9, "text_content": "RIS Fax 'server \n1/30/2018 8:03:40 AM PAGE \n4/004 \nFax Sarver \nMild s \nercd polypoid paranasal sinus mucosal thickening with an occluded left frontal drainage \nA0.5 cm right midpo = thyroid nodule. \nLeft \nel i \nlipoma, unchanged. \nMultilevel cervical epondylosis. \nVery truly yours, \nADAM1MLNER, M.D. \nElectronically Signed By. ADAM 1NILNER, M.D. \nDate/Time Transcribed: 1/30/18 9:02am \nContrast: Omnipague Contrast 350mg 100cc \nCreatinine 1.2mgkii \nREPORT \nCC: \nCC PATIENT \nEPSTEIN JEFFREY ACCT \nExam Date: 1/30118 DOB: \nEAST RIVER MEDICAL IMAGING, PC \nwww.aastriverlmagIng.com \nPRT/CT• HIGH FIELD MAI • OPEN MW • Al ULTIDETECTOR VOLUME CT (VT) • BONE DENSITY• NUCLEAR MEDICINE \nULTRASOUND • DIGITAL X-RAY• CORONARY CT ANOIOORA PRY• VIRTUAL COLONOSCOPY • CTIAIR ANGIOGRAPHY \nEFTA00314234\n", "char_count": 789}, {"efta_number": "EFTA00314225", "page_number": 10, "text_content": "At \nMount \nSinai \nRony Shlmony, MD \n486 Madison Ave \n17th Floor \nNew York, NY 10022 \nNuclear Medicine Associates \nNuclear SePET Imaging \n1 Gustave Low Place #1141 \nNow York, Nit 10029 \n(212) 241.6969 \n(212)831-2M (fax) \nPatient: EPSTEIN, JEFFREY \nSinai MR#: \nDOB: \nAccession #: \nDate of Exam: 12/1312017 \nExamination: NM PARATHYROID SCAN \n123 DOSING \nDear Dr. Shimony: \nSTUDY: Dual Isotope Parathyroid scan \nINDICATION: The patient presents with hypercalcemia, evaluate for parathyroid adenoma. \nMETHOD: The patient received 0.2 mCi of I-123 orally. Anterior pinhole views of the neck were then \nobtained. Then the patient received 20 ma of Tc-99m Sestamibi Intravenously. Anterior pinhole views of \nthe neck are obtained immediately followed by SPECT-CT Images of the neck and chest. Again, pinhole \nviews of the neck at 2 hours are obtained. The low- dose nondiagnostlo CT scan images were obtained \nsolely for the purpose of anatomic co-registration with the SPECT images. \nFINDINGS: There Is no prior study for comparison. \nThe I-123 thyroid image shows homogeneous radlotracer distribution In both lobes of the thyroid gland. \nThe early Sestamkil Image shows homogeneous radlotracer distribution In both lobes of the thyroid \ngland. \nThe delayed Sestamibl image shows equal radlotracer washout from both lobes of the thyroid gland. \nSPECT-CT images show no abnormal focal uptake In the neck or chest. \nIMPRESSION: \nTHERE IS NO ABNORMAL FOCAL UPTAKE IN THE NECK OR CHEST TO SUGGEST \nPARATHYROID ADENOMA. \nThank you for the courtesy of this referral. \nSincerely, \nSherif I Melba, MD \n(Electronically Signed) \nContrtbuling ProvIdor(c): \n1) Melba, Sherif I 2) KESTENBAUM, DAVID \nEFTA00314235\n", "char_count": 1693}, {"efta_number": "EFTA00314225", "page_number": 11, "text_content": "Surgery Office Clinic Note \nEpstein, Jeffrey E -\nFinal Report * \n* Final Report * \nReferring Physician \nDr. Bruce Moskowitz \nfridocrinolggist \nNone \nChief Complaint \nPrimary Hyperparathyroidism \nHistory of Present Illness \nMr. Epstein, Jeffrey is a 65-year-old male who presents for surgical evaluation and \ntreatment, referred by Dr. Bruce Moskowitz. The patient presents with the diagnosis \nof Primary Hyperparathyroidism and Hypercalcemia. The patient became aware of \nthe problem for about 10 years. He was previously evaluated by myself at Yale. At \nthat time, surgery was differed. \nThe patient does have a history of nephrollthiasis (2 episodes 6 years \nago). The patient does not take any thiazide diuretics or lithium. \nHis symptoms include constipation, trouble concentrating, and exacerbated fatigue. \nHe experiences these symptoms sporadically and they correlate with elevated PTH \nand calcium levels. The patient has no complaints of hoarseness, dysphagia, or \ndifficulty breathing. The patient has no history of radiation treatment to head or \nneck. Laboratory and imaging are listed below. I have reviewed all laboratory \nresults and images in details \nLaboratory Studies, August 16th, 2018 (Quest Diagnostics) \nBUN: 21 [7-25] \nCreatinine: 1.16 [0.70-1.25] \neGFR: 66 (>60] \nCalcium: 9.8 [8.6-10.3] it was 10.7 last week \nPTH, Intact: 94 (14-64] \nVitamin D, 25-OH: 32 [30-100] \nTSH: 2.31 [0.40-4.50] \nFree T4: 2.4 [1.4-3.8] \nT 150 (250-800) according to the patient his LH and FSH are both normal \nas per patient had a 24 hour urine for calcium which was normal. \nDiagnostic Imaging and Procedures \nParathyroid Scan, December 2017 (Mount Sinai, New York): \nIMPRESSION: There is no abnormal focal uptake In the neck or chest to suggest \nparathyroid adenoma. \nResult type: \nResult date: \nResult status: \nResult title: \nPerformed by: \nVerified by: \nEncounter info: \nSurgery Office Clinic Note \nAugust 20, 2018 13:40 EDT \nAuth (Verified) \nEndocrine Surgery Consultation \nAlonso, Rafael ARNP\n... [truncated, 2639 chars — for the full page use /api/corpus/document/EFTA00314225/11 or ?id=EFTA00314225&page=11]", "char_count": 2639}, {"efta_number": "EFTA00314225", "page_number": 12, "text_content": "Surgery Office Clinic Note \nEpstein, Jeffrey E - \n* Final Report \" \nNeck CT (4D Parathyroid Technique), January 2018 (East River Medical \nImaging, New York): \nIMPRESSION: \nNo evidence for parathyroid adenoma. \nMild scattered polypoid paranasal sinus mucosal thickening with an occluded left \nfrontal drainage pathway. \nA 0.5 cm right mid pole thyroid nodule. \nLeft supradavicular lipoma, unchanged. \nMultilevel cervical spondylolysis. \nPara Ultrasound \nNegative \nBone density: as per patient was normal \nReview of Systems \nCONSTITUTIONAL: No fever, weight loss, or night sweats. \nEYES: No visual changes or eye pain. \nENT: No sore throat, sinus pain, or ear pain. \nCARDIOVASCULAR: No chest pain or palpitations. \nRESPIRATORY: No cough, wheeze, or shortness of breath. \nGASTROINTESTINAL: No abdominal pain, nausea, or vomiting, + constipation \nENDOCRINE: As above only. \nMUSCULOSKELETAL: No musculoskeletal pain or joint swelling. \nNEUROLOGICAL: No changes in special senses, no headaches. \nIMMUNOLOGY: No swollen lymph nodes \nHEMATOLOGY: No easy bruising or history of excessive bleeding. \nINTEGUMENTARY: No rashes or skin lesions. \nALL OTHER: Negative \nPhysical Exam \nVitals & Measurements \nT: 37.2 °C (Oral) HR: 77 (Peripheral) RR: 16 BP: 123/74 SpO2: 96% \nWT: 88.5 kg (Measured) BMI: 27.01 \nPhysical exam reveals a well•developed male \nGENERAL: No resting tremors \nEYES: Conjunctivae are not injected. No sclera' icterus. No exophthalmos. \nCARDIOVASCULAR: Regular rate and rhythm without murmurs, rubs, or gallops. \nNo carotid bruits. \nRESPIRATORY: Lungs are clear to percussion and auscultation. \nMUSCULOSKELETAL: No muscular atrophy. Gait normal. \nSKIN: Normal skin turgor, no obvious bruising. \nNEUROLOGIC: Oriented X3. Motor and sensory grossly Intact. \nTHYROID: Examination of the neck reveals a normal thyroid gland. \nVOCAL CORDS: I was unable to visualize his cords by mirror exam. \nHEMATOLOGY/LYMPHATICS: There is no cervical or supraclavicular \nlymphadenopathy. \nResult type: \nResult date\n... [truncated, 2430 chars — for the full page use /api/corpus/document/EFTA00314225/12 or ?id=EFTA00314225&page=12]", "char_count": 2430}, {"efta_number": "EFTA00314225", "page_number": 13, "text_content": "Surgery Office Clinic Note \nEpstein, Jeffrey E \n• Final Report \nAssessment/Plan \n1. Primary hyperparathyroldism E21.0 \n--laboratory: 24 hour urine for calcium and creatinine \n-- Educational session and booklet provided to the patient \nThis patient almost certainly has minor primary HPTH with a history of \nnephrolithiasis and neurocognitive symptoms. His imaging is negative making him \nat higher risk for multi-gland disease. I do believe he would be best served by \nparathyroid surgery and I explained this In detail. He will obtain his 24 hr urine \ncollection in West Palm Beath and we will that after this study. \n-- I had a detailed conversation with the patient about his options. Based on the \nmost current laboratory values, imaging studies, and physical examination, I have \nrecommended: [Parathyroid exploration with the Intact PTH assay]. I \nexplained the procedure as well as the risks, benefits, and potential complications \nto the patient. Risks include, but are not limited to, bleeding, infection, \nhypocalcemia, reaction to anesthesia, and injury to the nerves near the vocal \ncords. The patient verbalized understanding and has no further questions. We will \nproceed to surgery at a time convenient for the patient. \nI, Dr. Robert Udelsman had a face-to-face encounter with this patient, \nexamined the patient and reviewed the APP notes. I have formulated \nthe assessment and plan for this patient and reviewed them with the \npatient. \nA total of 40 minutes were spent face-to-face with the patient during this \nencounter and over half of the time was spent counseling and coordination of \ncare. Discussed the operation, potential complications, post-operative recovery \nand management, past medical records including laboratory data and diagnostic \nimaging available at the time of the consult. \nDr. Bruce Moskowitz is thanked for involving me in the care of this interesting \npatient. \nRobert Udelsman, MD, MBA, FAGS, FACE \nEndocrine Neoplasia Institute \nMiami Cancer Institute \n\n... [truncated, 2565 chars — for the full page use /api/corpus/document/EFTA00314225/13 or ?id=EFTA00314225&page=13]", "char_count": 2565}, {"efta_number": "EFTA00314225", "page_number": 14, "text_content": "Surgery Office Clinic Note \nEpstein, Jeffrey E - \nFinal Report' \nElectronically Signed on 08/20/2018 14:49 \nUdelsman, Robert MD \nCompleted Action List: \n* Perform by Alonso, Rafael ARNP on August 20, 2018 13:42 EDT \n* Modify by Alonso, Rafael ARNP on August 20, 2018 13:51 EDT \n* Modify by Alonso, Rafael ARNP on August 20, 2018 13:51 EDT \n* Modify by Alonso, Rafael ARNP on August 20, 2018 13:53 EDT \n* Modify by Alonso, Rafael ARNP on August 20, 2018 13:53 EDT \n* Modify by Alonso, Rafael ARNP on August 20, 2018 13:53 EDT \n* Modify by Alonso, Rafael ARNP on August 20, 2018 14:12 EDT \n* Modify by Alonso, Rafael ARNP on August 20, 2018 14:16 EDT \n* Modify by Alonso, Rafael ARNP on August 20, 2018 14:17 EDT \n* Modify by Alonso, Rafael ARNP on August 20, 2018 14:19 EDT \n* Modify by Alonso, Rafael ARNP on August 20, 2018 14:20 EDT \n* Modify by Udelsman, Robert MD on August 20, 2018 14:49 EDT \n* Sign by Udelsman, Robert MD on August 20, 2018 14:49 EDT Requested by Alonso, Rafael ARNP on August 20, \n2018 14:40 EDT \n* VERIFY by Udelsman, Robert MD on August 20, 2018 14:49 EDT \n* Sign by Alonso, Rafael ARNP on August 21, 2018 07:33 EDT Requested by Alonso, Rafael ARNP on August 20, 2018 \n13:42 EDT \nResult type: \nResult date: \nResult status: \nResult title: \nPerformed by: \nVerified by: \nEncounter info: \nSurgery Office Clinic Note \nAugust 20, 2018 13:40 EDT \nAuth (Verified) \nEndocrine Surgery Consultation \nAlonso, Rafael ARNP on August 20, 2018 13:42 EDT \nUdelsman, Robert MD on August 20, 2018 14:49 EDT \n903306115, MCI, Clinic, 08/20/2018 - \nPrinted by: Cuevas, Yessenia OSHA \nPage 4 of 4 \nPrinted on: 08/24/2018 11:21 EDT \n(End of Report) \nEFTA00314239\n", "char_count": 1665}]}